Photocure

Photocure ASA, 'The Bladder Cancer Company,' is a commercial-stage biopharmaceutical firm dedicated to improving the diagnosis and management of bladder cancer through its photodynamic technology platform. Its approved product, Hexvix, enhances the accuracy of cystoscopy procedures, leading to better patient outcomes and reduced recurrence rates. The company is actively pursuing partnerships, AI integration, and new clinical data to solidify its position as a leader in urologic oncology diagnostics while maintaining a strong commitment to ESG principles.

Photodynamic Diagnosis (PDD) platform using the proprietary photosensitizer hexaminolevulinate, which causes cancer cells to fluoresce under blue light during cystoscopy, dramatically improving visualization and resection of bladder tumors.

Total raised: $23M

Main competitors include standard white light cystoscopy, narrow-band imaging (NBI) cystoscopy from major endoscope manufacturers, and urinary biomarker tests. Photocure differentiates with its drug-device combination that offers superior sensitivity for detecting carcinoma in situ (CIS), a strong focus on bladder cancer, and a growing body of health economic evidence supporting its value.